Boston Scientific’s Taxus Element
This article was originally published in The Gray Sheet
Enrollment begins for the PERSEUS clinical trial of Boston Scientific's third-generation paclitaxel-eluting stent July 13. The platinum chromium Taxus Element features thinner struts, more flexibility and a lower profile than previous Taxus models, the firm says. The PERSEUS program includes two components. The 1,264-patient Workhorse study will compare Taxus Element with Taxus Express2 in coronary lesions 2.75 to 4.0 millimeters in length. The primary endpoint is target lesion failure at 12 months. The second component is the 223-patient Small Vessel study comparing Taxus Element with a historical control in coronary lesions 2.25 to 2.75 millimeters long. The primary endpoint is in-stent late loss at nine months...
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.